OVID Ovid Therapeutics Inc.
Nasdaq · SEC CIK 1636651 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $29.3K 2 sales by 2 insiders
- Filings on record
- 77 since 2021-07-01, latest 2026-07-08 16:31
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| ALEXANDER MARGARET A. | Pres, CEO, Dir | — | $16.9K |
| Rona Jeffrey A | CBFO | — | $12.4K |
| Fitzgerald Kevin Joseph | Dir | — | — |
| Carter Charles Ross | CFO | — | — |
| Takeda Pharmaceuticals U.S.A., Inc. | 10% | — | — |
| Friedman Bart | Dir | — | — |
| LEVIN JEREMY M | Executive COB, Dir | — | — |
| PAPADOPOULOS STELIOS | Dir | — | — |
Transactions 25
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-08 16:31 | 2026-07-06 | OVID | Carter Charles Ross | CFO | A - Grant | $0.00 | +50.0K | 94.4K | +113% | $0 | |
| 2026-04-09 17:15 | 2026-04-07 | OVID | PAPADOPOULOS STELIOS | Dir | A - Grant | $2.56 | +17.6K | 217.6K | +9% | +$45.0K | |
| 2026-04-09 17:15 | 2026-04-07 | OVID | Friedman Bart | Dir | A - Grant | $2.56 | +8,789 | 8,789 | New | +$22.5K | |
| 2026-04-09 17:15 | 2026-04-07 | OVID | Fitzgerald Kevin Joseph | Dir | A - Grant | $2.56 | +17.6K | 17.6K | New | +$45.0K | |
| D | 2026-03-25 | 2026-03-23 | OVID | LEVIN JEREMY M | Executive COB, Dir | M - OptEx | $1.40 | +47.3K | 3.74M | +1% | +$66.3K |
| D | 2026-03-02 | 2026-02-26 | OVID | Rona Jeffrey A | CBFO | A - Grant | $0.00 | +68.1K | 156.3K | +77% | $0 |
| D | 2026-03-02 | 2026-02-23 | OVID | Rona Jeffrey A | CBFO | S - Sale | $1.45 | -8,541 | 88.2K | -9% | -$12.4K |
| D | 2026-03-02 | 2026-02-23 | OVID | ALEXANDER MARGARET A. | Pres, CEO, Dir | S - Sale | $1.45 | -11.7K | 61.8K | -16% | -$16.9K |
| D | 2025-12-18 | 2025-12-15 | OVID | LEVIN JEREMY M | CEO, Dir | C - Cnv Deriv | — | +71.0K | 3.69M | +2% | — |
| DI | 2025-12-09 | 2025-12-08 | OVID | Takeda Pharmaceuticals U.S.A., Inc. | 10% | C - Cnv Deriv | $0.00 | +1.25M | 7.00M | +22% | $0 |
| 2025-02-28 | 2025-02-26 | OVID | ALEXANDER MARGARET A. | Pres, COO | S - Sale | $0.56 | -5,279 | 73.4K | -7% | -$2,956 | |
| 2025-02-28 | 2025-02-26 | OVID | Rona Jeffrey A | CBFO | S - Sale | $0.56 | -3,902 | 68.0K | -5% | -$2,185 | |
| D | 2025-02-24 | 2025-02-20 | OVID | ALEXANDER MARGARET A. | Pres, COO | A - Grant | $0.00 | +43.8K | 78.7K | +125% | $0 |
| D | 2025-02-24 | 2025-02-20 | OVID | Rona Jeffrey A | CBFO | A - Grant | $0.00 | +43.8K | 71.9K | +156% | $0 |
| 2025-01-29 | 2025-01-27 | OVID | ALEXANDER MARGARET A. | Pres, COO | P - Purchase | $0.73 | +6,810 | 34.9K | +24% | +$4,971 | |
| 2024-03-20 | 2024-03-18 | OVID | LEVIN JEREMY M | CEO, Dir | P - Purchase | $2.76 | +18.2K | 3.62M | +0.5% | +$50.4K | |
| D | 2024-02-26 | 2024-02-22 | OVID | Perone Thomas Michael | GC, Sec | A - Grant | $0.00 | +28.1K | 28.1K | New | $0 |
| D | 2024-02-26 | 2024-02-22 | OVID | Rona Jeffrey A | CBFO | A - Grant | $0.00 | +28.1K | 28.1K | New | $0 |
| D | 2024-02-26 | 2024-02-22 | OVID | Tardio Jason | COO | A - Grant | $0.00 | +28.1K | 28.1K | New | $0 |
| AI | 2024-02-14 | 2019-09-20 | OVID | LEVIN JEREMY M | CEO, Dir | G - Gift | $0.00 | -465.1K | 0 | -100% | $0 |
| M | 2023-12-06 | 2023-12-04 | OVID | LEVIN JEREMY M | CEO, Dir | G - Gift | $0.00 | -1.15M | 4.17M | -22% | $0 |
| 2022-09-14 | 2022-09-12 | OVID | Tardio Jason | COO | S - Sale | $2.15 | -17.3K | 0 | -100% | -$37.3K | |
| DMI | 2022-07-06 | 2022-07-01 | OVID | TAKEDA PHARMACEUTICAL CO LTD | 10% | J - Other | $0.00 | 0 | 5.75M | New | $0 |
| D | 2021-07-16 | 2021-07-14 | OVID | Rakhit Amit | Pres, CMO | M - OptEx | $1.89 | +34.0K | 760.8K | +5% | +$64.3K |
| D | 2021-07-16 | 2021-07-14 | OVID | Rakhit Amit | Pres, CMO | S - Sale+OE | $3.71 | -34.0K | 726.8K | -4% | -$126.2K |
Purchase Sale Sale after option exercise All abbreviations